According to Zacks, “Theravance’s sole marketed product, Vibativ, continued to perform well, with the product growing year over year. Moreover, Theravance’s efforts on the commercialization of Vibativ are encouraging. We are also positive on the company’s efforts on label expansion of the drug, which if approved for additional indications, would be commercially significant. Further, its collaboration agreement with Mylan for revefenacin, a key late-stage pipeline candidate, is a big positive. Estimates have been moving up lately ahead of the company’s third-quarter 2016 earnings release. However, the company relies heavily on Vibativ for growth, which is concerning. As a result, lower-than-expected sales of the drug would hurt the company’s top line significantly. The company expects lot of activity on the pipeline front for the rest of 2016. Any hiccup on the development front could pull down the stock significantly.”
Other equities research analysts have also issued research reports about the company. Evercore ISI initiated coverage on Theravance Biopharma in a research note on Monday, August 29th. They set a buy rating and a $41.00 price target on the stock. Leerink Swann restated a buy rating and set a $31.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, August 9th. Guggenheim assumed coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a buy rating and a $30.00 price objective for the company. Robert W. Baird downgraded Theravance Biopharma from a neutral rating to an underperform rating and lifted their price objective for the stock from $19.00 to $24.00 in a research report on Wednesday, October 12th. Finally, Bank of America Corp. downgraded Theravance Biopharma from a neutral rating to an underperform rating in a research report on Wednesday, August 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $35.40.
Theravance Biopharma (NASDAQ:TBPH) opened at 30.56 on Friday. The stock’s market capitalization is $1.46 billion. Theravance Biopharma has a 52-week low of $12.87 and a 52-week high of $38.92. The stock’s 50 day moving average price is $33.23 and its 200 day moving average price is $25.59.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative return on equity of 70.79% and a negative net margin of 471.82%. On average, analysts forecast that Theravance Biopharma will post ($4.03) EPS for the current year.
In other Theravance Biopharma news, SVP Brett K. Haumann sold 9,509 shares of the business’s stock in a transaction on Friday, August 19th. The stock was sold at an average price of $27.97, for a total value of $265,966.73. Following the completion of the transaction, the senior vice president now directly owns 197,391 shares in the company, valued at approximately $5,521,026.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Bradford J. Shafer sold 49,122 shares of the business’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total value of $1,348,890.12. Following the completion of the transaction, the executive vice president now owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The disclosure for this sale can be found here. 4.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TBPH. OMERS ADMINISTRATION Corp increased its position in shares of Theravance Biopharma by 21.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 13,828 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 2,419 shares during the period. Bellevue Group AG acquired a new position in shares of Theravance Biopharma during the first quarter valued at $215,000. PNC Financial Services Group Inc. increased its position in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 192 shares during the period. Bank of New York Mellon Corp increased its position in shares of Theravance Biopharma by 25.4% in the second quarter. Bank of New York Mellon Corp now owns 179,769 shares of the biopharmaceutical company’s stock valued at $4,079,000 after buying an additional 36,397 shares during the period. Finally, Swiss National Bank increased its position in shares of Theravance Biopharma by 19.8% in the second quarter. Swiss National Bank now owns 53,942 shares of the biopharmaceutical company’s stock valued at $1,224,000 after buying an additional 8,900 shares during the period. Institutional investors own 69.97% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.